Comerica Bank boosted its position in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 20,133.7% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 35,409 shares of the company's stock after purchasing an additional 35,234 shares during the quarter. Comerica Bank's holdings in Dyne Therapeutics were worth $834,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors have also recently added to or reduced their stakes in DYN. KBC Group NV grew its holdings in Dyne Therapeutics by 45.3% in the 4th quarter. KBC Group NV now owns 3,135 shares of the company's stock valued at $74,000 after buying an additional 978 shares during the period. Summit Investment Advisors Inc. grew its holdings in Dyne Therapeutics by 9.1% in the 4th quarter. Summit Investment Advisors Inc. now owns 8,627 shares of the company's stock valued at $203,000 after buying an additional 721 shares during the period. KLP Kapitalforvaltning AS purchased a new stake in Dyne Therapeutics in the 4th quarter valued at about $257,000. Magnetar Financial LLC purchased a new stake in Dyne Therapeutics in the 4th quarter valued at about $263,000. Finally, E Fund Management Co. Ltd. grew its holdings in Dyne Therapeutics by 11.8% in the 4th quarter. E Fund Management Co. Ltd. now owns 11,848 shares of the company's stock valued at $279,000 after buying an additional 1,249 shares during the period. Institutional investors and hedge funds own 96.68% of the company's stock.
Insiders Place Their Bets
In other Dyne Therapeutics news, insider Oxana Beskrovnaya sold 2,598 shares of the company's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $13.95, for a total value of $36,242.10. Following the completion of the transaction, the insider now owns 199,087 shares in the company, valued at $2,777,263.65. This represents a 1.29% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold a total of 6,237 shares of company stock worth $77,760 in the last 90 days. 14.14% of the stock is owned by company insiders.
Wall Street Analysts Forecast Growth
Several analysts have commented on the company. Piper Sandler lowered their price target on Dyne Therapeutics from $53.00 to $48.00 and set an "overweight" rating for the company in a report on Friday, February 28th. BMO Capital Markets assumed coverage on Dyne Therapeutics in a report on Wednesday, March 12th. They issued an "outperform" rating and a $50.00 price target for the company. Scotiabank assumed coverage on Dyne Therapeutics in a report on Friday, March 7th. They issued a "sector outperform" rating and a $50.00 price target for the company. JPMorgan Chase & Co. lowered their price target on Dyne Therapeutics from $18.00 to $17.00 and set a "neutral" rating for the company in a report on Friday, March 21st. Finally, Chardan Capital restated a "buy" rating and issued a $50.00 price target on shares of Dyne Therapeutics in a report on Friday, May 9th. One analyst has rated the stock with a sell rating, one has issued a hold rating, twelve have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $46.85.
Read Our Latest Stock Report on DYN
Dyne Therapeutics Stock Performance
Shares of NASDAQ:DYN traded up $0.09 during trading on Friday, reaching $11.83. 2,185,589 shares of the stock were exchanged, compared to its average volume of 1,677,802. Dyne Therapeutics, Inc. has a 12-month low of $6.36 and a 12-month high of $47.45. The firm has a market cap of $1.34 billion, a price-to-earnings ratio of -3.32 and a beta of 1.19. The firm's 50-day moving average price is $10.36 and its 200 day moving average price is $17.51.
Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($1.05) earnings per share for the quarter, missing analysts' consensus estimates of ($0.88) by ($0.17). As a group, equities research analysts forecast that Dyne Therapeutics, Inc. will post -3.44 EPS for the current year.
About Dyne Therapeutics
(
Free Report)
Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.
See Also
Before you consider Dyne Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dyne Therapeutics wasn't on the list.
While Dyne Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
